Related Experiment Video

Updated: Jun 21, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77

Cristiano Ferlini1, Lucia Cicchillitti, Giuseppina Raspaglio

  • 1Laboratory of Antineoplastic Pharmacology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy. cferlini@rm.unicatt.it

Cancer Research
|August 13, 2009
PubMed

Insights

Paclitaxel targets Bcl-2, initiating apoptosis. It mimics the peptide Nur77, which also binds Bcl-2 and beta-tubulin, suggesting new cancer drug development avenues.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Bcl-2 is paradoxically down-regulated in paclitaxel-resistant cancer cells.
  • Paclitaxel is a widely used chemotherapy agent.
  • The precise mechanism of paclitaxel's action on Bcl-2 is not fully understood.

Purpose of the Study:

  • To elucidate the direct interaction between paclitaxel and Bcl-2.
  • To investigate the potential of paclitaxel as a mimic of endogenous ligands.
  • To explore novel therapeutic strategies for paclitaxel-resistant cancers.

Main Methods:

  • Molecular modeling to analyze binding sites of paclitaxel.
  • Biochemical assays to confirm interactions between paclitaxel, Bcl-2, and beta-tubulin.
  • Functional studies using Nur77 and peptide mimics to assess biological effects.

Main Results:

  • Paclitaxel directly targets the loop domain of Bcl-2, promoting apoptosis.
  • Molecular modeling revealed shared binding sites for paclitaxel on Bcl-2 and beta-tubulin.
  • Nur77 was confirmed to interact with both Bcl-2 and beta-tubulin, mimicking paclitaxel's effects on tubulin polymerization and mitochondrial pore opening.

Conclusions:

  • Paclitaxel's action involves direct targeting of Bcl-2, distinct from its known interaction with beta-tubulin.
  • The findings suggest paclitaxel acts as a mimic of endogenous peptides like Nur77.
  • This research opens avenues for developing novel, non-taxane anticancer agents and identifying patient subsets responsive to paclitaxel.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Examining BCL-2 Family Function with Large Unilamellar Vesicles08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...